272 related articles for article (PubMed ID: 10397533)
21. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
French M; Keane N; McKinnon E; Phung S; Price P
HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
[TBL] [Abstract][Full Text] [Related]
22. Update on opportunistic infections.
Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
[TBL] [Abstract][Full Text] [Related]
23. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
[TBL] [Abstract][Full Text] [Related]
25. High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States.
Gebo KA; Fleishman JA; Reilly ED; Moore RD;
Med Care; 2005 Sep; 43(9 Suppl):III23-30. PubMed ID: 16116306
[TBL] [Abstract][Full Text] [Related]
26. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
27. Opportunistic infections update.
Proj Inf Perspect; 1998 Apr; (24):17-9. PubMed ID: 11365715
[TBL] [Abstract][Full Text] [Related]
28. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.
Ekwaru JP; Campbell J; Malamba S; Moore DM; Were W; Mermin J
J Int AIDS Soc; 2013 Apr; 16(1):17355. PubMed ID: 23547778
[TBL] [Abstract][Full Text] [Related]
29. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.
Coakley EP; Samore MH; Gillis JM; Hughes MD; Hammer SM
AIDS; 2000 Jun; 14(9):1147-53. PubMed ID: 10894278
[TBL] [Abstract][Full Text] [Related]
30. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality.
Seage GR; Losina E; Goldie SJ; Paltiel AD; Kimmel AD; Freedberg KA
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):421-8. PubMed ID: 12138349
[TBL] [Abstract][Full Text] [Related]
31. Opportunistic infections: stemming the tide.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Apr; 3(4):42-7. PubMed ID: 11364202
[TBL] [Abstract][Full Text] [Related]
32. Opportunistic infections: down but not out.
Bishai WR; Chaisson RE
Hopkins HIV Rep; 1999 Mar; 11(2):2, 7, 12. PubMed ID: 11366247
[TBL] [Abstract][Full Text] [Related]
33. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.
Asch SM; Gifford AL; Bozzette SA; Turner B; Mathews WC; Kuromiya K; Cunningham W; Andersen R; Shapiro M; Rastegar A; McCutchan JA
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):340-4. PubMed ID: 11707670
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting.
Manosuthi W; Chaovavanich A; Tansuphaswadikul S; Prasithsirikul W; Inthong Y; Chottanapund S; Sittibusaya C; Moolasart V; Termvises P; Sungkanuparph S
J Infect; 2007 Nov; 55(5):464-9. PubMed ID: 17714788
[TBL] [Abstract][Full Text] [Related]
35. [The characteristics of opportunistic infections in 181 HIV/AIDS patients in China].
Wang XC; Huang XJ; Zhang T; Liang LC; Jiao YM; Zhang HW; Wu H
Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):379-82. PubMed ID: 17637305
[TBL] [Abstract][Full Text] [Related]
36. Discontinuing Pneumocystis carinii prophylaxis.
Girard PM
N Engl J Med; 2001 Jan; 344(3):222-3. PubMed ID: 11172146
[No Abstract] [Full Text] [Related]
37. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
[TBL] [Abstract][Full Text] [Related]
38. Impact of opportunistic disease on survival in patients with HIV infection.
Chaisson RE; Gallant JE; Keruly JC; Moore RD
AIDS; 1998 Jan; 12(1):29-33. PubMed ID: 9456252
[TBL] [Abstract][Full Text] [Related]
39. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
[TBL] [Abstract][Full Text] [Related]
40. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Kim S; Hughes MD; Hammer SM; Jackson JB; DeGruttola V; Katzenstein DA
AIDS Res Hum Retroviruses; 2000 May; 16(7):645-53. PubMed ID: 10791875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
